SCHEMBL2759043

SCHEMBL2759043

Cc1cc(N(CCO)CCO)ccc1C(c1ccc(Cl)cc1)c1ccc(N(CCO)CCO)cc1C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.75
LMNA P02545 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
TP53 P04637 1/20 0.75
ATM Q13315 1/20 0.75
NPSR1 Q6W5P4 1/20 0.75
MAPT P10636 4/20 0.66
GAA P10253 1/20 0.66
PKM P14618 1/20 0.66
HTT P42858 1/20 0.66
MCL1 Q07820 1/20 0.66
MEN1 O00255 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
MMP14 P50281 1/20 0.43
RAB9A P51151 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
UTS2R Q9UKP6 7/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2759021 0.86 KMT2A (1.00) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL5097333 0.84 ATM (0.52) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL12342190 0.83 MAPT (0.55) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL5009578 0.83 MAPT (0.59) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL20100523 0.81 MAPT (0.59) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL2759083 0.80 KMT2A (0.69) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL7650155 0.80 MAPT (0.61) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL2759054 0.80 MAPT (1.00) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL12342189 0.78 MAPT (0.50) KMT2ALMNASMN1; SMN2TP53ATM
SCHEMBL12342187 0.77 MAPT (0.58) KMT2ALMNASMN1; SMN2TP53ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828330-B2 Non-peptide BDNF neurotrophin mimetics PHARMATROPHIX, INC. (US) 2017-11-28 US disclosed
US-9828330-B2 Non-peptide BDNF neurotrophin mimetics PHARMATROPHIX, INC. (US) 2017-11-28 US disclosed
US-20160046559-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX, INC. (US) 2016-02-18 US disclosed
US-20160046559-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX, INC. (US) 2016-02-18 US disclosed
US-20140296343-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX, INC. 2014-10-02 US disclosed
US-20140296343-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX, INC. 2014-10-02 US disclosed
WO-2014144342-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX, INC. (US) 2014-09-18 WO disclosed
US-20120004310-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX, INC. 2012-01-05 US disclosed
US-20120004310-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX, INC. 2012-01-05 US disclosed
WO-2011150347-A2 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS PHARMATROPHIX (US) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004310-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS BDNF, NTRK2, NGF KMT2A 3890/4885LMNA 3046/4885SMN1; SMN2 34/4885
US-20160046559-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS NTRK2, BDNF, NTRK1 KMT2A 3852/4885LMNA 2805/4885SMN1; SMN2 47/4885
US-20140296343-A1 NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS BDNF, NTRK2, NGF KMT2A 3890/4885LMNA 3046/4885SMN1; SMN2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.